Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
- MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017
- Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
- Alminoprofen Reclassified as Class 1 OTC Drug: MHLW
July 13, 2017
- Osaka Prefecture to Conduct Surprise Onsite Inspections of API Manufacturing Facilities in Wake of Acetaminophen Scandal
July 13, 2017
- Retired Vice Minister Happy to See Stage Set for Timely Price Revisions
July 12, 2017
- MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
- Further Transformation beyond Pricing Overhaul Inevitable: Outgoing MHLW Economic Affairs Chief
July 10, 2017
- Applications for Partial Modification to Suffice to Change Manufacturing Processes for Biopharmaceuticals: MHLW Notification
July 7, 2017
- MHLW to Enhance Awareness about Tougher Controls on Private Importing of Drugs by Doctors
July 7, 2017
- MHLW Floats Standard Processing Time for Cost-Effective Assessments: Chuikyo
July 6, 2017
- Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
- Drugs Containing Codeine to Be Contraindicated in Children Younger than 12: MHLW Notifications
July 6, 2017
- Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017
- Add Sclerosing Cholangitis to ADR List in Opdivo Label: MHLW
July 5, 2017
- MHLW OKs Spinraza, Tenelia-Canaglu Combo, and More
July 4, 2017
- MHLW Calls for Surprise Inspection for API Makers
July 3, 2017
- Revised GPSP Ministerial Ordinance Will Establish“Post-Marketing Database Surveys”: MHLW
July 3, 2017
- MHLW to Provide Administrative Guidance in 23 Cases of Ethical Drug Advertising Activities
July 3, 2017
- MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…